Questions of durability came up regarding Curis Inc.’s latest data with CA-4948, but that didn’t stop shares from soaring to $6.55 by day’s end, an increase of $5.11, or 355%. The ride came after Lexington, Mass.-based Curis rolled out positive preliminary data from the firm’s ongoing open-label, single-arm phase I dose-escalation study with the compound.
As expected, the FDA cleared Biocryst Pharmaceuticals Inc.’s oral, once-daily Orladeyo (berotralstat, formerly known as BCX-7353) for the prevention of hereditary angioedema (HAE) attacks. Last month, Biocryst, as part of its earnings report, said approvals of the compound, a kallikrein inhibitor evaluated by U.S. regulators without an advisory committee meeting, could come in Japan this month and in the EU by the first half of next year.
Frontier Medicines Corp. co-founder, chairman and CEO Chris Varma told BioWorld that his firm’s deal with Abbvie Inc. happened by way of a “highly competitive process, thankfully, with multiple parties at the table,” and the tie-up means money that could “well exceed” $1 billion.
The already intriguing IL-2 pathway as a therapeutic target gained still more traction after San Francisco-based Nektar Therapeutics Inc. unveiled melanoma data with bempegaldesleukin (bempeg), its CD122-preferential agent in the class.
The whopper deal between Biogen Inc. and Sage Therapeutics Inc. – a global collaboration and licensing deal involving the latter’s zuranolone (also known as SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders, as well as SAGE-324 for essential tremor (ET) and neurological disorders – drew mixed reviews from Wall Street. And, for Biogen investors, the would-be Alzheimer’s disease (AD) therapy aducanumab remains front of mind.
New York-based Hookipa Pharma Inc.’s positive interim data from a phase II study with what could become the first approved cytomegalovirus (CMV) vaccine, HB-101, lifted shares (NASDAQ:HOOK) to a high of $13.25 early in the day but the price leveled off later to close Nov. 30 at $11.60.
A new report on the biopharma industry by cybersecurity firm Bluevoyant LLC found that the eight most prominent players in the race for a COVID-19 vaccine faced the highest volume of targeted, malicious cyberattacks, and 77% of the total 20 companies examined had unsecured remote desktop protocol (RDP) ports and email domains lacking basic measures to block hackers. “COVID-19 vaccines are the crown jewels of 2020 – and cyber attackers know it,” the report says.
Although Eiger Biopharmaceuticals Inc. sees more would-be opportunities with ultra-rare disease-targeting Zokinvy (lonafarnib), the company’s vice president of clinical and development operations, Colin Hislop, said that “at the moment, we’re very clearly focused on the population identified in the label, because it fits most closely with the mechanism of action.”